全文获取类型
收费全文 | 18236篇 |
免费 | 1215篇 |
国内免费 | 123篇 |
专业分类
耳鼻咽喉 | 191篇 |
儿科学 | 253篇 |
妇产科学 | 244篇 |
基础医学 | 2451篇 |
口腔科学 | 434篇 |
临床医学 | 1678篇 |
内科学 | 3672篇 |
皮肤病学 | 504篇 |
神经病学 | 2077篇 |
特种医学 | 1201篇 |
外科学 | 3496篇 |
综合类 | 106篇 |
一般理论 | 5篇 |
预防医学 | 595篇 |
眼科学 | 201篇 |
药学 | 1165篇 |
中国医学 | 13篇 |
肿瘤学 | 1288篇 |
出版年
2023年 | 154篇 |
2022年 | 112篇 |
2021年 | 432篇 |
2020年 | 340篇 |
2019年 | 448篇 |
2018年 | 512篇 |
2017年 | 422篇 |
2016年 | 512篇 |
2015年 | 639篇 |
2014年 | 774篇 |
2013年 | 869篇 |
2012年 | 1478篇 |
2011年 | 1581篇 |
2010年 | 963篇 |
2009年 | 896篇 |
2008年 | 1320篇 |
2007年 | 1343篇 |
2006年 | 1263篇 |
2005年 | 1183篇 |
2004年 | 1066篇 |
2003年 | 973篇 |
2002年 | 913篇 |
2001年 | 180篇 |
2000年 | 131篇 |
1999年 | 159篇 |
1998年 | 121篇 |
1997年 | 147篇 |
1996年 | 56篇 |
1995年 | 80篇 |
1994年 | 68篇 |
1993年 | 46篇 |
1992年 | 55篇 |
1991年 | 44篇 |
1990年 | 39篇 |
1989年 | 36篇 |
1988年 | 29篇 |
1987年 | 20篇 |
1986年 | 27篇 |
1985年 | 14篇 |
1984年 | 15篇 |
1983年 | 12篇 |
1982年 | 10篇 |
1981年 | 6篇 |
1980年 | 9篇 |
1979年 | 6篇 |
1978年 | 8篇 |
1975年 | 6篇 |
1974年 | 5篇 |
1973年 | 5篇 |
1970年 | 4篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
Anne-Sophie Worm Fenger Markus Harboe Olsen Maria Louise Fabritius Christian Gunge Riberholt Kirsten Møller 《Acta anaesthesiologica Scandinavica》2023,67(2):240-247
Background
Hyperglycaemia is common in patients with acute brain injury admitted to an intensive care unit (ICU). Many studies have found associations between development of hyperglycaemia and increased mortality in hospitalised patients. However, the optimal target for blood glucose control is unknown. We want to conduct a systematic review with meta-analysis and trial sequential analysis to explore the beneficial and harmful effects of restrictive versus liberal glucose control on patient outcomes in adults with severe acute brain injury.Methods
We will systematically search medical databases including CENTRAL, Embase, MEDLINE and trial registries. We will search the following websites for ongoing or unpublished trials: http://www.controlled-trials.com/ , http://www.clinicaltrials.gov/ , www.eudraCT.com , http://centerwatch.com/ , The Cochrane Library's CENTRAL, PubMed, EMBASE, Science Citation Index Expanded and CINAHL. Two authors will independently review and select trials and extract data. We will include randomised trials comparing levels of glucose control in our analyses and observational studies will be included to address potential harms. The primary outcomes are defined as all-cause mortality, functional outcome and health-related quality of life. Secondary outcomes include serious adverse events including hypoglycaemia, length of ICU stay and duration of mechanical ventilation, and explorative outcomes including intracranial pressure and infection. Trial Sequential Analysis will be used to investigate the risk of type I error due to repetitive testing and to further explore imprecision. Quality of trials will be evaluated using the Cochrane Risk of Bias tool, and quality of evidence will be assessed using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach.Discussion
The results of the systematic review will be disseminated through peer-reviewed publication. With the review, we hope to inform future randomised clinical trials and improve clinical practice. 相似文献3.
Siegler Benedikt Hermann Oehler Beatrice Kranke Peter Weigand Markus Alexander 《Der Anaesthesist》2022,71(8):646-660
Die Anaesthesiologie - Der Postpunktionskopfschmerz („postdural puncture headache“, PDPH) zählt zu den wesentlichen Komplikationen der peripartalen neuroaxialen Analgesie. Als... 相似文献
4.
Matthias Knefel PhD Elisabeth L. Zeilinger PhD Simone Lubowitzki PhD Katharina Krammer MSc Matthias Unseld MD Rupert Bartsch MD Thorsten Fuereder MD Ulrich Jäger MD Barbara Kiesewetter MD Maria Krauth MD Markus Raderer MD Philipp B. Staber MD Peter Valent MD Alexander Gaiger MD 《Cancer》2023,129(21):3466-3475
Background
Survival in cancer patients is associated with a multitude of biological, social, and psychological factors. Although it is well established that all these factors add to overall mortality, it is not well understood how the predictive power of these parameters changes in a comprehensive model and over time.Methods
Patients who attended the authors’ outpatient clinic were invited to participate. The authors followed 5180 mixed cancer patients (51.1% female; mean age, 59.1 years [SD = 13.8]) for up to 16 years and analyzed biological (age, sex, cancer site, anemia), psychological (anxiety, depression), and social variables (marital status, education, employment status) potentially predicting overall survival in a Cox proportional hazards model.Results
The median survival time for the entire sample was 4.3 years (95% confidence interval, 4.0–4.7). The overall survival probabilities for 1 and 10 years were 76.8% and 38.0%, respectively. Following an empirical approach, the authors split the time interval into five periods: acute, subacute, short-term, medium-term, and long-term. A complex pattern of variables predicted overall survival differently in the five periods. Biological parameters were important throughout most of the time, social parameters were either time-independent predictors or tended to be more important in the longer term. Of the psychological parameters, only depression was a significant predictor and lost its predictive power in the long-term.Conclusions
The findings of this study allow the development of comprehensive patient-specific models of risk and resilience factors addressing biopsychosocial needs of cancer patients, paving the way for a personalized treatment plan that goes beyond biomedical cancer care. 相似文献5.
Schneider Ralph Dettmer Marius Peters Nora Lamdark Tenzin Luedi Markus M. Adamina Michel Doll Dietrich 《European Surgery》2022,54(2):117-125
European Surgery - Treatment of pilonidal sinus disease (PSD) requires a tailored approach. A national guideline was published in 2014. The current status of surgical PSD therapy... 相似文献
6.
7.
Wessel Theda Heuing Katharina Schlangen Miriam Schnieders Birgit Algermissen Markus 《Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz》2022,65(11):1119-1125
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz - Menschen mit Seltenen Erkrankungen stehen im Gesundheitssystem vor besonderen Herausforderungen. Die Seltenheit der einzelnen... 相似文献
8.
Die Anaesthesiologie - Im Jahr 1989 haben die Vereinten Nationen die „United Nations Convention on the Rights of the Child“ (UNCRC) beschlossen und u. a. für Kinder der... 相似文献
9.
Marco Bandini Sebastiano Nazzani Michele Marchioni Felix Preisser Zhe Tian Marco Moschini Firas Abdollah Nazareno Suardi Markus Graefen Francesco Montorsi Shahrokh F. Shariat Fred Saad Alberto Briganti Pierre I. Karakiewicz 《Clinical genitourinary cancer》2019,17(1):72-78.e4
Background
The rate of noninterventional treatment (NIT) in prostate cancer (PCa) active surveillance (AS) candidates is on the rise. However, contemporary data are unavailable. We described community-based NIT rates within 16 Surveillance Epidemiology and End Results (SEER) registries between 2010 and 2014.Patients and Methods
We identified 23,360 PCa patients who fulfilled the University of California San Francisco AS criteria (prostate-specific antigen [PSA] < 10 ng/mL, clinical T stage ≤ T2a, Gleason score ≤ 6, and positive cores < 33%). Annual NIT rates as well as patient distribution according to PSA, age, number of positive cores, and clinical T stage were studied. Multivariable logistic regression analysis tested NIT predictors.Results
Between 2010 and 2014, the NIT rate increased from 30.2% to 57.5% (P = .004). Within 16 SEER registries, NIT rates ranged from 25.9% to 62%. NIT rate increased uniformly within all examined registries. Of patient and tumor characteristics (PSA > 4 ng/mL, cT2a and > 1 positive core) only the proportion of NIT patients aged < 65 years increased over time from 47.3% to 53.2% (P = .03). By multivariable logistic regression analysis predicting NIT rate, older age (odd ratio [OR] = 1.05), more contemporary year of diagnosis (OR = 1.41), and being unmarried (OR = 1.45) and uninsured (OR = 2.41) were independent predictors.Conclusion
The NIT rate has markedly increased across all examined SEER registries. Nonetheless, important differences distinguish those who received high-end NIT from low-end NIT. PCa characteristics of NIT patients remained unchanged over time. However, in addition to geographical differences in NIT rates, patient characteristics such as age, marital status, and insurance status represent potential NIT access barriers. 相似文献10.
Christopher L. Heidler Eva K. Roth Markus Thiemann Claudia Blattmann Ramon L. Perez Peter E. Huber Michal Kovac Beate Amthor Gabriele Neu-Yilik Andreas E. Kulozik 《International journal of cancer. Journal international du cancer》2020,147(4):1059-1070
Progress in the systemic control of osteosarcoma has been limited over the past decades thus indicating the urgent clinical need for the development of novel treatment strategies. Therefore, we have recently developed new preclinical models to study promising novel agents for the treatment of pediatric osteosarcoma. The checkpoint kinase (chk) inhibitor prexasertib (LY2606368) and its salt form (LSN2940930) have recently been shown to be active in adult and pediatric malignancies, including sarcoma. We have now tested the potency of prexasertib in clonogenic survival assays in two new lines of primary patient-derived osteosarcoma cells and in two established osteosarcoma cell lines as a single agent and in combination with cisplatin and the poly ADP-ribose polymerase (PARP) inhibitor talazoparib. Prexasertib alone results in strongly reduced clonogenic survival at low nanomolar concentrations and acts by affecting cell cycle progression, induction of apoptosis and induction of double-stranded DNA breakage at concentrations that are well below clinically tolerable and safe plasma concentrations. In combination with cisplatin and talazoparib, prexasertib acts in a synergistic fashion. Chk1 inhibition by prexasertib and its combination with the DNA damaging agent cisplatin and the PARP-inhibitor talazoparib thus emerges as a potential new treatment option for pediatric osteosarcoma which will now have to be tested in preclinical primary patient derived in vivo models and clinical studies. 相似文献